Recruitment of study subjects to Peptonic Medical’s phase 2b study off to a good start
Stockholm 13th June 2016. - Peptonic Medical AB (publ) (“the Company” or “Peptonic”) – a company developing pharmaceuticals based on oxytocin – today announced that 57 study subjects have been randomised in to its phase 2b study since the start of the study six weeks ago. During the month of June an additional 13 subjects are due to be randomised. The aim of the study is to investigate the effect of Vagitocin® (oxytocin) for the treatment of vaginal atrophy.The phase 2b study is a double-blind, placebo-controlled, multicenter study and comprise two arms of 80 patients each, in total 160